|
1. Biologie
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
5. Traitements
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
Halozyme Inks $105M Bristol-Myers Partnership, Expands Roche Deal [Xconomy]
|
|
|
|
|
|
The
Roche deal announced Thursday builds on one of Halozyme’s longest
business relationships. In 2006, Roche licensed Halozyme’s technology to
develop up to 13 compounds. So far, the collaboration has yielded
injectable formulations of Roche cancer drugs trastuzumab (Herceptin)
and rituximab (MabThera).
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
Hemo-oncology newbie Bayer gears up for copanlisib launch [FiercePharma]
|
|
|
|
|
|
If
Bayer can snag an FDA approval—based on phase 2 results that showed
copanlisib could provoke a response in 58.7% of relapsed or refractory
follicular lymphoma patients, completely ridding 14.4% of them of
cancer—it’ll go up against Gilead’s Zydelig, a med in copanlisib’s PI3K
class that’s also approved for patients who have received two or more
therapies.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.9 AACR
|
|
|
|
6.1 Observation
|
|
|
|
6.11 Patients
|
|
|
|
6.6 Publications
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|
|
|